Fennec Pharmaceuticals Inc.FRX.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · United States · fennecpharma.com
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company headquartered in Research Triangle Park, North Carolina, focused on PEDMARK® (sodium thiosulfate injection), an FDA-approved therapy for reducing cisplatin-induced hearing loss in pediatric patients with solid tumors. The company's shares trade on both the NASDAQ (FENC) and the Toronto Stock Exchange (FRX).
Key ratios
FCF / Sales
-27.9%TTM
2025
-27.9%2024
56.8%2023
-80.7%
Net margin
-21.8%TTM
2025
-21.8%2024
-0.9%2023
-75.5%
ROA
-6.8%TTM
2025
-6.8%2024
4.5%2023
-29.7%
ROE
-65.8%TTM
2025
-65.8%
Recent news
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Track FRX.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer